Big Net Income From Continuing Ops from 2010 to 2026
| PRM Stock | CAD 14.40 -0.09 -0.62% |
Net Income From Continuing Ops | First Reported 2010-12-31 | Previous Quarter 11.6 K | Current Value 11 K | Quarterly Volatility 1.5 M |
Macro event markers
Evaluating Big Pharma's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Big Pharma Split's fundamental strength.
Latest Big Pharma's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Big Pharma Split over the last few years. It is Big Pharma's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Big Pharma's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Big Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 980,624 | |
| Coefficient Of Variation | 152.21 | |
| Mean Deviation | 1,176,593 | |
| Median | 323,221 | |
| Standard Deviation | 1,492,609 | |
| Sample Variance | 2.2T | |
| Range | 5M | |
| R-Value | 0.16 | |
| Mean Square Error | 2.3T | |
| R-Squared | 0.02 | |
| Significance | 0.55 | |
| Slope | 45,909 | |
| Total Sum of Squares | 35.6T |
Big Net Income From Continuing Ops History
Methodology, Assumptions & Data Sources
Long-run Net Income From Continuing Ops data for Big Pharma anchors current readings against a multi-year baseline. Comparing this metric against sector peers can reveal relative positioning.
Data shown for Big Pharma Split is aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Source publication cadence can introduce delays. This section presents reference data and historical patterns only and does not constitute an investment recommendation or advice.